Apellis Pharmaceuticals, Inc. Q3 2025 Earnings Recap

APLS Q3 2025 November 1, 2025

Get alerts when APLS reports next quarter

Apellis Pharmaceuticals delivered a strong third quarter in 2025, highlighted by the FDA approval of EMPAVELI for C3 glomerulopathy, enhancing its market position with differentiated treatment options.

Earnings Per Share Beat

$1.67 vs $1.03 est.

+62.1% surprise

Revenue Beat

458578000 vs 199276020 est.

+130.1% surprise

Market Reaction

1-Day +0.0%

5-Day -8.2%

30-Day +0.56%

See APLS alongside your other holdings

Add to your portfolio — free

Key Takeaways

EMPAVELI's approval increases the addressable market by approximately 5,000 patients, positioning it as the only comprehensive treatment for multiple patient populations.
Early feedback on EMPAVELI's launch has been overwhelmingly positive, with physicians emphasizing its efficacy and ease of use via a compact auto-injector.
SYFOVRE continues to face slow adoption despite its proven clinical profile, prompting strategic marketing initiatives aimed at accelerating growth in the geographic atrophy market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit APLS on AllInvestView.